POSITIONING OF TB DX : TIERED SYSTEM, INTEGRATED APPROACH

Similar documents
How best to structure a laboratory network with new technologies

Technology and innovation: Changing dynamics of TB control. Karin Weyer

Ken Jost, BA, has the following disclosures to make:

TB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai

Xpert MTB/RIF assay validation experience --- impact and plan in China

Health Care Worker Training on Roll Out New TB Diagnostic Test. Prepared by: City Health (J Caldwell) & NHLS (M Bosman & I Noordien)

When good genes go bad

A roadmap for TB laboratory strengthening within WHO policy frameworks and national laboratory strategies

Diagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013

India s Contribution in Rolling out Newer and Rapid Diagnostics towards PMDT Scale-up

Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014

Report of TB/HIV Diagnostics Task Force. Barbara Laughon NIAID, NIH

TB Laboratory for Nurses

Receipt within 1 day of specimen collection. Report AFB b smear result within 1 day from receipt of specimen

National Xpert MTB/RIF Programme

TB Intensive San Antonio, Texas November 11 14, 2014

NAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL

The innovation gaps and challenges for MDR-TB. Blessina Kumar TB/ HIV Activist Community Representative & Vice Chair STBP Coordinating Board

CULTURE OR PCR WHAT IS

Treating Patients, Not Disease: People-Centered Approach

Progress Report March 2016

Diagnosis of drug resistant TB

Overview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing

Diagnosis of tuberculosis

TB 101 Disease, Clinical Assessment and Lab Testing

WHO recommendations. Diagnostic testing in infants

Trends in molecular diagnostics

TB Diagnostics: Global Market Analysis and Potential

Kritische Fragen zum Beitrag der kombinierten PCR für den Nachweis von M. tuberculosis und der Identifizierung von Mutationen auf dem rpob-gen

Mycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf

DST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps?

Nucleic Acid Amplification Testing for the Diagnosis of TB

Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis

Research Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012

Diagnosis of tuberculosis in children

MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT

Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor

New frontiers: Innovation and Access

Introduction. Diagnosis of extrapulmonaryand paediatric tuberculosis. Extrapulmonary tuberculosis EPTB SASCM WORKSHOP 2014/05/24

Stacy White, PhD May 12, TB for Community Providers. Phoenix, Arizona

Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER

Xpert MTB/RIF Training. Indira Soundiram 2012

CDPH - CTCA Joint Guidelines Guideline for Micobacteriology Services In California

Grant Summary Report: Expansion of Nucleic Acid Amplification Testing for TB In Public Health Laboratories

GeneXpert (Xpert MTB/RIF): what is the future?

Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.

Alere q A Molecular Platform for Global Health Diagnostics

TOG The Way Forward

Vision and strategies to Increase Access to Innovative HIV Diagnostic Technologies. Willy Urassa. AMD STAKE HOLDERS MEETING 7-8 May 2013

Progress Report July 2014

Cepheid The MDx Growth Leader. William Blair Growth Stock Conference June 12, 2012

Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis

Policy Framework for Implementing New Tuberculosis Diagnostics

Planning for the implementation of new diagnostic tests

The MODS Assay for Detection of TB and TB Drug Resistance: A Multi-center Study

Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests

The Lancet Infectious Diseases

TB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

STOCS-H Scottish TOC Study HPV test comparison

Rapid Diagnostics CHAI Experience. 6 th Moving Forward in Diagnostics Forum Les Pensieres November 7, 2012

TB Update: March 2012

Detection of Multidrug Resistance and Characterization of Mutations in Mycobacterium tuberculosis Isolates in Raichur District, India

MIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex

APHL Global Health TB-related Activities

Principles of laboratory diagnosis of M. tuberculosis. Anne-Marie Demers, MD, FRCPC 11 September 2017

Schedules of different training programs planned at NITRD under this WHO CC are given in the NITRD-WHOCC Training Schedules booklet.

TB is Local. Barry Chin, Boston Globe, 10/15/2008. * BUT only in appropriate setting

Harmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis

IHI Biomedical Sciences Group. Joseph Mugasa, PhD, PD. Stakeholders Meeting

Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults(review)

Rapid Diagnostic Techniques for Identifying Tuberculosis Ken Jost November 13, 2008

General Session IV - Dale Schwab April 20, 2017

Xpert MTB/RIF. implementation manual. Technical and operational how-to : practical considerations IMPLEMENTATION MANUAL TUBERCULOSIS PERFORMANCE

Can new diagnostics make a difference?

Balancing investment in point of care diagnostics versus laboratory testing in low resource settings. June 28, 2011

A retrospective evaluation study of diagnostic accuracy of Xpert MTB/RIF assay, used for detection of Mycobacterium tuberculosis in Greece

Use of the Cepheid GeneXpert to Release Patients from Airborne Isolation

New Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention

Diagnosing Xpert MTB/RIF negative TB suspects: Impact and cost of an alternative algorithm

Target product profiles for next generation TB diagnostics. Claudia Denkinger, MD PhD MSc Head of TB, FIND

Original Article Evaluation of Xpert MTB/RIF in detection of pulmonary and extrapulmonary tuberculosis cases in China

Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB. Global Consultation

Dr Francis Ogaro MTRH ELDORET

Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults (Review)

Advanced TB Diagnostic Research

Nucleic Acid Amplification Test for Tuberculosis. Heidi Behm, RN, MPH Acting TB Controller HIV/STD/TB Program Oregon, Department of Health Services

The first National TB Prevalence Survey Rwanda 2012

Alere Technologies GmbH

Revised National Tuberculosis Control Programme

Modelling Innovative Diagnostic Tools for Tuberculosis

Towards Harmonization of Mycobacteriology in TB Trials. Study 31/ACTG 5349 Key Elements of Mycobacteriology Laboratory Procedures

Trends in Testing for Mycobacterium tuberculosis Complex from US Public Health Laboratories,

New Standards for an Old Disease:

Evaluation of Genxpert Real Time PCR POC in the Diagnosis of Multidrug Resistant TB Among Patients Attending NTBLTC Saye-Zaria Nigeria

Innovations in nucleic acid amplification technologies. Automated platforms for NAT. Microfluidics Digital PCR Innovations in nucleic acid microarrays

Jefferies Healthcare Conference. John Bishop Chairman & CEO June 2, 2014

EXPERT GROUP MEETING REPORT

Transcription:

POSITIONING OF TB DX : TIERED SYSTEM, INTEGRATED APPROACH Akos Somoskövi, M.D., Ph.D. and Giorgio Roscigno, M.D. ANNUAL GLI MEETING, 4 th OCTOBER 2010 MERIEUX FOUNDATION, ANNECY

Integrated Laboratory Network Definition An integrated laboratory network can be defined as one that has the ability to provide all needed primary diagnostic services for care and treatment of patients without requiring them to go to different laboratory facilities for specific tests (under one roof ideally under one ceiling).

Integrated Laboratory Network laboratory services and emerging infectious diseases TB HIV Malaria Growth detection and DST Reference level 5% of patients Molecular testing Chemistry/haematology Regional and district level 35% of patients Microscopy RDT Community and health care center Specimen collection and transportation/ reporting 60% of patients 3

Importance of early diagnosis: Sensitivity (cfu/ml) of pulmonary TB tests in portfolio Target sensitivity range of FIND antigen detection test for TB in sputum fluorescent microscope 10,000/ml Capilia* speciation dipstick (of culture) 1,000,000/ml LAMP-TB 50-150/ml Line-probe* 10,000/ml Liquid Culture 10-100/ml Automated NAAT 50-150/ml 0 1 2 3 4 5 6 Log cful/ml 4 * Development completed

Introducing high tech in low tech settings Major advantages in workflow GeneXpert Automated Sample Prep, Amplification and Detection <120 minutes fully automated with 1-step external sample prep. time-to-result 1 1/2 h (walk away test) throughput: up to 16 tests / module / run no bio-safety cabinet closed system (lower contamination risk) Performance A technology platform: TB & Rif Resistance Potential for HIV viral load Potential for HPV STD specific for MTB sensitivity close to culture detection of rif-resistance via rpob gene 5

GeneExpert Platforms GeneXpert Infinity-48 GeneXpert Module GX-1 GX-4 GX-16

Diverse Testing Needs WOMEN S HEALTH / STDs CRITICAL INFECTIOUS DISEASE HEALTHCARE ASSOCIATED INFECTIONS IMMUNO- COMPROMISED ONCOLOGY GENETICS Roche GenProbe Qiagen BD Abbott biomérieux

Integration of new tools in the tiered health system Surveillance Reference methods Network supervision Resolution testing (screening-test negative drug resistance) Regional Labs Reference Labs LC / DST 15d/ 30d SC / DST LC / DST 30d / 15d 60d/ 30d In house DST (MODS, NRA, CRI) Special settings and conditions LPA Rif / INH 2d Early Infant DX HIV District Level Screening Passive case finding Detect and treat SubDistrict Level ZN 2-3d Integrated NAAT +40% /2h Sputum neg./hiv pos. HIV Viral Load 2012 HPV STD 2012 Microscopy Level LED FM +10% Manual NAAT+25% EID HIV 2011 Malaria HAT Clinical Screening Primary care Community Level RDT Gen1 / Gen 2

Further questions to be answered The eligible patient to be tested Smear + and/ or Low and high HIV settings Low and high MDR settings Any case or only any drug resistant suspect or only MDR suspects Backup culture and DST capacity to follow up MDR/XDR patients Specimen referral EQA Adequate diagnostic algorithm

Integrating HIV-TB diagnostics platforms: Lesotho MDR-TB LPA EID for HIV by PCR Molecular laboratory in Maseru Demonstration (Evidence) March 2007 LC April 2008 LPA WHO (Policy) June 2007 LC June 2009 LPA Implementation (Practice) November 2007 LC November 2008 LPA April 2009 EID for HIV by PCR Partners WHO PIH MOH (Lesotho)

National TB Reference Laboratory Maseru, Lesotho: Integrated TB-HIV (EID) laboratory Number of TB diagnostic tests performed (2009 to July 2010) Testing Platform ~ MGIT 960- Liquid culture Line probe assay** Tests performed MTB Positive DST tests* MDR- TB MDR-patients placed on treatment 7081 712 241 116 102 652 563 563 117 90 *Only MDR-TB suspects request for DST; ** rapid DST for 'rif' and 'inh - data includes QA/Training activities ~ In addition: Solid culture and DST for 951 DRS samples and LED FM microscopy demonstration study in 2008-2009

Number of EID HIV* diagnostic tests performed (Jan- July 2010) Total tests Positive Placed on treatment 722 137 35 * EID-Early infant diagnosis of HIV-1 DNA Early infant Diagnosis of HIV using Dried Blood samples Punching of DBS cards DNA extraction Hybridization reading of plate 12

Thank you 13